Displaying 132 (all) recruiting clinical trials.
-
A Phase 1/1b Open-label Multicenter Study to Investigate the Safety Tolerability Pharmacokinetics and Antitumor Activity of KIN-2787 in Participants with BRAF and/or NRAS Mutation-positive Solid Tumors.
You can participate in this study if you are diagnosed with stage 3 or stage 4 skin melanoma. The purpose of this study is to ... -
Prospective Randomized Placebo-Controlled Trial of SurVaxM Plus Adjuvant Temozolomide for Newly Diagnosed Glioblastoma (SURVIVE)
You can participate in this study if you are newly diagnosed with brain cancer (glioblastoma). The purpose of this study is to evaluate a peptide ...
-
Melanoma Margins Trial (MelMarT): A Phase III Multi-Centre Multi-National Randomised Control Trial Investigating 1cm v 2cm Wide Excision Margins for Primary Cutaneous Melanoma.
You can participate in this study if you are diagnosed with skin melanoma stage 2. This study will determine whether there is a difference in ... -
Compassionate Use of Pirtobrutinib for a Patient with Waldenstrom s macroglobulinemia.
You can participate in this study if you are diagnosed with Waldenstrom’s macroglobulinemia. In this study we will evaluate the study drug (Pirtobrutinib) for ...
-
A Phase 1 Open-Label Multicenter Study to Assess Safety Tolerability PK and Efficacy of MK-1084 as Monotherapy and in Combination With Pembrolizumab in Subjects with KRASG12C Mutant Advanced Solid Tumors
You can participate in this study if you are diagnosed with any of the advanced solid tumors found in any of the organ systems. The ... -
A PHASE 1 STUDY OF TJ033721 IN SUBJECTS WITH ADVANCED OR METASTATIC SOLID TUMORS.
You can participate in this study if you are diagnosed with advanced solid tumors. The purpose of this study is to test the safety of ... -
A Phase 1/2a Multicenter Open-Label Non-Randomized First in Human Study to Assess the Safety Tolerability Pharmacokinetics and Preliminary Antitumor Activity of DB-1303 in Patients with Advanced/Metastatic Solid Tumors.
You can participate in this study If you are diagnosed with HER2-positive or HER2-expressing advanced/unresectable, recurrent tumor that is refractory to or intolerable with ... -
EMBER-4: A Randomized Open-Label Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients who have Previously Received 2 to 5 years of Adjuvant Endocrine Therapy for ER+ HER2- Early Breast Cancer with an Increased Risk of Recurrence.
You can participate in this study if you are diagnosed with ER+, HER2- Early Breast Cancer (Stages I-III) with an Increased Risk of Recurrence. And ... -
Integrating Financial Coaching and Smoking Cessation Coaching
The purpose of this research study is to test a program that combines financial coaching with quit smoking coaching and nicotine replacement therapy (nicotine gum ... -
An Open-Label Prospective Multi-Center Randomized Clinical Trial to Evaluate The Efficacy and Safety Of TheraSphere Followed by Durvalumab (Imfinzi ) With Tremelimumab Versus TheraSphere Alone For Hepatocellular Carcinoma (HCC)
The purpose of this study is to objectively evaluate skin color changes during and after standard of care breast or chest wall radiotherapy using spectrophotometry ...